

## Original Article

### **Increased platelet distribution width and reduced IL-2 and IL-12 are associated with thrombocytopenia in *Plasmodium vivax* malaria**

Allyson Guimarães Costa<sup>1,2,3,4,5</sup>, Yury Chaves<sup>6</sup>, Andréa Teixeira-Carvalho<sup>7,8</sup>, Rajendranath Ramasawmy<sup>1,2,9</sup>; Lis Ribeiro Valle Antonelli<sup>7,8</sup>, Lucas Barbosa<sup>6</sup>, Antonio Balieiro<sup>6</sup>, Wuelton Marcelo Monteiro<sup>1,2</sup>, Maria Paula Mourão<sup>1,2</sup>; Marcus Vinicius Guimarães Lacerda<sup>1,2,4,6</sup>, Olindo Assis Martins-Filho<sup>7,8</sup>, Fabio Trindade Maranhão Costa<sup>10</sup>, Adriana Malheiro<sup>1,3,4,5</sup>, Paulo Afonso Nogueira<sup>2,5,6\*</sup>

<sup>1</sup>Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil

<sup>2</sup>Instituto de Pesquisa Clínica Carlos Borborema, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (FMT-HVD), Manaus, Amazonas, Brazil

<sup>3</sup>Diretoria de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil

<sup>4</sup>Programa de Pós-Graduação em Ciências Aplicadas à Hematologia, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil

<sup>5</sup>Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil

<sup>6</sup>Instituto Leônidas & Maria Deane, Fundação Oswaldo Cruz, Manaus, Amazonas, Brazil.

<sup>7</sup>Grupo Integrado de Pesquisas em Biomarcadores, Centro de Pesquisas René Rachou (CPqRR-FIOCRUZ/ MG), Belo Horizonte, Minas Gerais, Brazil.

<sup>8</sup>Laboratório de Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.

<sup>9</sup>Faculdade de Medicina, Universidade Nilton Lins, Manaus, AM, Brazil

<sup>10</sup>Instituto de Biologia, Universidade Estadual de Campinas, SP, Brazil.

Received 23 February 2020

Accepted 26 June 2020

\*Corresponding author: [paulo.nogueira@fiocruz.br](mailto:paulo.nogueira@fiocruz.br)

Orcid number: 0000-0003-3015-1021

<sup>4</sup>Instituto Leônidas & Maria Deane, Fundação Oswaldo Cruz, Manaus, Amazonas, Brazil.

The full list of author information is available at the end of the paper.

## Abstract

**Background:** Thrombocytopenia in malaria involves platelet destruction and consumption; however, the cellular response underlying this phenomenon has still not been elucidated.

**Objective:** To find associations between platelet indices and unbalanced Th1/Th2/Th17 cytokines as a response to thrombocytopenia in *Plasmodium vivax* infected (Pv-MAL) patients.

**Methods:** Platelet counts and quantification of Th1/Th2/Th17 cytokine levels were compared in 77 patients with uncomplicated *P. vivax* malaria and 37 healthy donors from the same area (endemic control group, ENCG).

**Results:** Thrombocytopenia was the main manifestation in 55 patients, but was not associated with parasitemia. The Pv-MAL patients showed increases in the mean platelet volume (MPV), which may be consistent with larger or megaplatelets. Contrary to the findings regarding the endemic control group, MPV and platelet distribution width (PDW) did not show an inverse correlation, due the increase in the heterogeneity of platelet width. In addition, the Pv-MAL patients presented increased IL-1 $\beta$  and reduced IL-12p70 and IL-2 serum concentrations. Furthermore, the reduction of these cytokines was associated with PDW values.

**Conclusions:** Our data demonstrate that an increase in MPV and the association between reductions of IL-2 and IL-12 and PDW values may be an immune response to thrombocytopenia in uncomplicated *P. vivax* malaria.

Keywords: platelet, *Plasmodium vivax*, IL-12p70, IL-2, IL-1 beta, thrombocytopenia

## **Background**

Thrombocytopenia is one of the most frequent hematological alterations in acute malaria infections involving *Plasmodium falciparum* and *Plasmodium vivax* malaria (Pv-MAL) [1]. Thrombocytopenia is prominent in patients with splenomegaly and can be found in patients whose spleen is not palpable [2,3]. Thrombocytopenia is not listed as a criterion for severe malaria, however, its clinical importance has been widely recognized when accompanied by multiple organ failures [4–8]. The mortality rate in vivax malaria patients with severe thrombocytopenia alone can be comparable to that of falciparum malaria when associated with other danger signs of malaria (such as seizures, jaundice, bleeding, among others), and these can serve as red flags in order to promptly identify patients who may have severe malaria [4,5,8–11].

The pathogenesis of thrombocytopenia caused by malaria involves multifactorial phenomenon and leads to destruction and consumption of platelets [12]. In particular, in falciparum malaria, platelets also bind diffusely in systemic microvasculature, rather than pooling in the liver or spleen [13–17]. Moreover, other pathophysiological mechanisms have recently been associated with thrombocytopenia caused by malaria, such as coagulopathy, splenic sequestration of damaged platelets, platelet aggregation, antibody-mediated platelet destruction and oxidative stress aggregation formation and dysmegakaryopoiesis [4,18–21]. In Pv-MAL, thrombocytopenia is also common, however its pathogenesis is less well-known.

Platelets are small disc-shaped cellular fragments with no nucleus and which have regenerated continuously from megakaryocyte (MK). The MKs are large,

polyploid cells that have lost their proliferative ability and have become progressively differentiated, creating an invaginated membrane system for platelet formation [22]. The steady state megakaryopoiesis is responsible for releasing of approximately  $100 \times 10^9$  platelets per day and lifespan is 7-10 days. Under inflammatory and thrombocytopenia conditions, such as malarial infection, platelet lifespan is reduced to 2-3 days and MKs differentiate in order to replenish platelets [23–25].

In general, thrombocytopenia in malaria is accompanied by both higher mean platelet volume (MPV) and larger platelet distribution width (PDW), which arise concomitantly with reduced platelet counts [18,19,26,27]. The increase in platelet volume is a result of the release of larger platelets in the circulation, also described as giant or mega platelets [4,20,21,28–33]. Mega platelets are larger than  $5 \mu\text{m}$  in the smear, and are found in the peripheral circulation when there is increase of megakaryocyte production, due to reduced platelet level in the body. Even if the presence of mega platelets is not identified in the smear, it is possible to detect the increase in platelet volume indirectly, by increasing the MPV. Mega platelets also have a greater amount of granules, which, consequently, increases their ability to adhere and aggregate. Mega platelets and increased MPV may indicate a compensatory premature release of platelets from the bone marrow in order to compensate for the lower absolute number of platelets in the periphery [4,20,28–31,33]. According to other studies, the megakaryocytic lineage is apparently preserved in bone marrow and able to release mega platelets [4,21,28]. Since the blood stream medullary response can be triggered by cytokines, our study assessed serum concentrations of Th1/Th2/Th17 cytokines,

in order to characterize a profile of the immune response in thrombocytopenia caused by *P. vivax* infections.

## Methods

### Study area and population

Seventy-seven Pv-MAL patients (diagnosed as confirmed cases via examination of the thick blood smear) were enrolled at the Tropical Medicine Institute in the municipality of Coari, Amazonas State, Brazil. Coari is located at latitude: -4.08488, Longitude: -63.1417; 4 ° 5'6 "South, 63 ° 8'30" West, in an area with a high incidence of malaria. It is estimated that approximately 30% of its inhabitants are at risk of malaria (annual parasitological index > 50). *P. vivax* is responsible for 99.6% of cases of malaria [34,35]. All the patients had classic malaria symptoms with no signs of severe or complicated malaria.

Parasitemia levels were defined as low parasitemia ( $\leq 500$  parasites/mm<sup>3</sup>) or mild ( $> 500$  parasites/mm<sup>3</sup>). Blood Cells were examined using an ABX Micros 60 hematology analyzer (Horiba). Thirty-seven healthy donors were included in the study to form an endemic control group (ENCG). These were health professionals who are residents of this area, who had no previous history of malaria and tested negative in two thick blood smear examinations which were performed at intervals of fifteen days. When detected, thrombocytopenia was classified as being either mild (50–150,000/mm<sup>3</sup>) or severe ( $< 50,000$ /mm<sup>3</sup>) [36].

A detailed serological screening was performed for hepatitis B virus, hepatitis C virus and HIV (Arquitect i2000SR, Abbott Diagnostics), and supervised by the

Blood Bank (HEMOAM). In addition, participants were also screened for dengue Virus by PCR. After malaria diagnosis, blood samples were collected in EDTA tubes (BD Biosciences, USA), and sent in thermal boxes (maintained at 4 °C) to the Molecular Biology Laboratory of the Federal University of Amazonas in Coari.

### **Ethical considerations**

All protocols and consent forms were approved by the Research Ethics Committee at HEMOAM, under approval No. 0014.0.112.000-11. Patients were treated according to recommendations of Brazilian Ministry of Health.

### **Serum cytokine measurements**

Frozen plasma samples were sent on dry ice to the Core Flow Cytometry Facility at the HEMOAM blood bank for cytokine measurement with the cocktail kit (CBA-BD/Biosciences Pharmingen, USA). The cytokines IL-2, IL-4, IL-5, IL-6, IL-10, TNF- $\alpha$ , IFN- $\gamma$  and IL-17A were measured according to manufacturer's instructions, and IL-1 $\beta$ , IL-8 (CXCL-8) and IL-12 (IL-12p70) were measured by ELISA (BD OptEIA Set II human kit, BD Biosciences Pharmingen, USA).

### **Statistical analysis and data presentation**

All data were analyzed using GraphPad prism software version 5. The Th1/Th2/Th17 cytokines levels were separated into non-thrombocytopenic, mild and severe thrombocytopenia according to platelet counts. Reference intervals for the platelet parameters according to the recommended European Federation of Clinical Chemistry and Laboratory Medicine were used [37]. In both analyses,

groups were compared with the endemic control group, which represented the basal state of cytokine levels. The Mann Whitney test was used to compare platelet counts and cytokine levels of Pv-MAL patients with those of the ENCG. In addition, platelet counts were compared among patients of the malaria group and classified into low and mild parasitemia. Spearman's rank correlation coefficient was used to assess the relationship between MPV and PDW indexes with platelet counts for the malaria group and endemic control group. A multinomial model classified the assessed platelet indices (Platelet counts, MPV and PDW indices) and cytokines between patients of the malaria group, and classified them as having either low or mild parasitemia. Finally, linear regression was performed to assess the predictors of thrombocytopenia in Pv-MAL patients in relation to the ENCG, taking into account platelet count indices and cytokine serum concentrations. An asterisk (\*) indicates a significance level of  $p < 0.05$ , (\*\*)  $p < 0.005$  and (\*\*\*)  $p < 0.0005$ .

## Results

All patients included in the study had uncomplicated paroxysms at the time of seeking medical care. None of the patients reported diarrhea or vomiting. Fifty-three (68.8%) patients were male and twenty-four (31.2%) were female. Fifteen of the patients (19.5%) reported primary malaria and sixty-two reported at least one previous malaria infection. None of the patients showed signs of anemia or severe malaria. Thirty patients had leukopenia (38.9%) and lymphopenia was evident in thirty-two patients (41.5%).

Thrombocytopenia was observed in fifty-five of seventy-seven patients (71.4%), also in five of the thirty-seven individuals in the ENCG. Thrombocytopenia was classified as being either moderate ( $51-149 \times 10^3$  platelets/ $\mu\text{L}$ ) or severe (below  $50 \times 10^3$  platelets/ $\mu\text{L}$ ). Among the patients, forty-four (80%) had moderate thrombocytopenia and eleven displayed severe thrombocytopenia (20%); none of the patients needed platelet transfusion. In Figure 1A, colored dots illustrate the Pv-MAL patients classified into non-thrombocytopenic, mild and severe thrombocytopenic individuals. The average age of the patients was  $37.0 \pm 14.3$  years, the age of Pv-MAL patients did not affect platelet count according to Spearman's rank correlation coefficient of 0.1373 (p-value=0.2338). Among the thirty-seven individuals used as the ENCG, three had moderate thrombocytopenia (8.1%) and two (5.4%) had severe thrombocytopenia and colored as thrombocytopenia status. The average age of the patients was  $29.4 \pm 8.45$  years in ENCG, though this did not influence the platelet count ( $r=0.2365$  and p-value= 0.0738).

Platelet counts were used to assess whether the thrombocytopenia caused by vivax malaria was due to peripheral destruction or bone marrow disease. The average MPV index in Pv-MAL patients was higher than the average in the ENCG, although both were within normal range (Figure 1B), and PDW values did not differ among the ENCG (Figure 1C). No patient presented high parasitemia. Thirty-eight patients (49.4%) had low parasitemia, with parasite counts being below five hundred parasites per milliliter ( $\leq 500$  parasites/ $\text{mm}^3$ ), while thirty-nine Pv-MAL patients (50.6%) showed moderate parasitemia (between 501 to 20,000 parasites/ $\text{mm}^3$ ). However, not all platelet indices differed in relation to parasitemia (Figure 2A-C).

In general, lower platelet counts are associated with higher platelet volumes [38]. Both groups showed an inverse correlation between mean platelet volume (MPV) and platelet counts (Figures 3A-D), though not in relation to PDW values (Figures 3B-E). It is also well known that PDW correlates with MPV in normal test subjects, and Figure 3C-F shows this correlation was lost in Pv-MAL patients.

The serum concentrations of Th1/Th2/Th17 cytokines were compared in the Pv-MAL patients and the endemic control group (Figure 4). Pv-MAL patients showed a reduction of IL-12p70 and IL-2 levels, while IL-1 $\beta$  was higher in relation to the ENCG (Figures 4). Other cytokines showed no differences in the comparison between groups.

To assess predictors of thrombocytopenia using cytokine levels of Th1/Th2/Th17 and platelet indices, a multinomial model was used to exclude parasitemia as a confounding factor (Table). For this, the serum levels of patients with mild parasitemia were used as a reference group (Table). We observed that the crude odds ratio in the serum concentrations of IL-10, and IL-17A increased individually in response to mild parasitemia. When Th1/Th2/Th17 cytokines and platelet indices were assessed together, the adjusted odds ratio for the serum concentration of IL-10 and IL-17A also increased in relation to the mild parasitemia group.

Finally, a linear regression was performed to assess predictors of thrombocytopenia in Pv-MAL patients in relation to the ENCG. Since the PDW index showed negative correlation with platelet counts, we used it as a dependent variable, while the other platelet indices and cytokine levels were considered independent variables (Table). The linear regression showed that the levels of IL-

1 $\beta$ , IL-2 and IL-12 were associated with altered PDW in Pv-MAL patients, and they may be predictors of the medullar response to thrombocytopenia caused by vivax malaria.

## **Discussion**

Thrombocytopenia is the most common hematological disorder in patients with malaria and one of the major concerns when accompanied by multiple organ failures [7,8]. In our study, thrombocytopenia was the main manifestation among patients with vivax malaria, though the reduction in platelet count was not associated with parasitemia. Although some patients presented severe thrombocytopenia, none of them presented bleeding. Very low platelet counts during malaria are considered transient, for those who do not present bleeding, platelet transfusions are unnecessary [23,39]. Platelet function is compromised in thrombocytopenia caused by malaria, and this is generally evidenced by changes in its parameters [28]. Here, the Pv-MAL patients displayed an increased MPV that may indirectly indicate the presence of mega platelets [4]. A negative correlation between platelet counts and MPV can be observed, but this inverse correlation is not restricted to malaria, since it is usually found in other physiological conditions [4,28,38,40–42]. Furthermore, we observed that an inverse correlation between MPV and PDW in the endemic control group was lost in Pv-MAL patients due a trend of increases in PDW and MPV.

The total platelet mass is considered as a product of platelet count X MPV, and this inverse correlation may be closely regulated [38,42]. Cytokine levels in malaria have dual effects in the pathogenesis of, and protection against, malaria [20,30,43]. The cytokine imbalance in thrombocytopenia caused by vivax malaria has been reported by several studies without a consensus about which cytokines could be associated to thrombocytopenia [4,20,21,27,30,32,44,45]. In this study, we assessed immune responses in relation to other parameters as well as platelet counts. Of all the cytokines, only IL-1 $\beta$ , IL-12 and IL-2 differed in *Pv-MAL* patients, and were associated with increases in the PDW values. Thus, the association of PDW with these differences may be considered a reduction of Th1 responses and thus the main mechanism which induces the elevation of MPV and PDW, in accordance with the findings of other authors [28].

Furthermore, parasitemia was associated with higher levels of IL-10 and a slight increase in the serum concentration of IL17A. Increased levels of IL-10 have already been seen in patients with higher parasitemia and patients with recurrent malaria [46–48]. Here, this imbalance in IL-10 and IL17A seems to be a shift from a pro-inflammatory response to an anti-inflammatory response, which explains the low frequencies of severe malarial disease among individuals living in endemic areas [49].

This study had several limitations. The sample size of patients was small and PCR for malaria diagnoses was not performed in all of those enrolled in this study. Nor did we evaluate antimicrobial failure. The population of the municipality of Coari is very well-informed about malaria and knows about the need to diagnose malaria at the onset of the disease, hence, this may explain why all the patients had uncomplicated malaria. Another limitation to the study was the semi-

quantification of parasites which is carried out in the Brazilian Amazon, and which made it impossible to assess further correlations, as also observed by a few other studies [28,50]. A further limitation to this study was that documentation of mega platelets was not done at the time of blood collection, however, the aim of the study was to assess changes in the immune response associated with thrombocytopenia. It is likely that the changes in MPV and PDW observed here may be due the release of the larger platelets also called as mega platelets or giant platelets [4,33]. These mega platelets may be detected indirectly by the increase in platelet volume in thrombocytopenia caused by malaria. The greater amount of  $\alpha$ -granules and dense granules enhance the mega platelets' ability of to adhere and aggregate with small platelets, as observed in peripheral blood smears of children infected with *Plasmodium falciparum* malaria [33]. These increases provide equal or similar primary hemostasis and may be the reason why bleeding episodes are rare in acute malaria infection, despite the thrombocytopenia [4,33] Thus, the reason for our assumption is that megakaryocytic lineage is apparently preserved in bone marrow and able to release mega platelets in the blood stream [4,21,28]. Our data encourage studies that assess the release of mega platelets in thrombocytopenia caused by *P. vivax* infections.

In conclusion, the increase in MPV indirectly indicated the presence of mega platelets. The loss of its correlation with PDW in Pv-MAL patients may also be a consequence of the release of mega platelets. The reduction of IL-2 and IL-12 associated with PDW may be consistent with regulation of immune response which is associated with appearance of mega platelets in thrombocytopenia caused by vivax malaria.

### **Author contributions**

AGC, AM, YC, LB, MPM, and PAN were responsible for the data collection from medical records. AB and WMM performed the statistical analysis. ACG, LB, ATC, OAMF, LRVA, AM participated in study design. ACG, AM, OAMF and PAN wrote the first draft of the manuscript. AGC, OAMF, RR, FTMC, MVGL and PAN elaborated the final version of manuscript. All authors read and approved the final manuscript.

### **Author details**


<sup>1</sup>Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil; <sup>2</sup>Instituto de Pesquisa Clínica Carlos Borborema, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (FMT-HVD), Manaus, Amazonas, Brazil; <sup>3</sup>Diretoria de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil; <sup>4</sup>Programa de Pós-Graduação em Ciências Aplicadas à Hematologia, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil; <sup>5</sup>Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil; <sup>6</sup>Instituto Leônidas & Maria Deane, Fundação Oswaldo Cruz, Manaus, Amazonas, Brazil; <sup>7</sup>Grupo Integrado de Pesquisas em Biomarcadores, Centro de Pesquisas René Rachou (CPqRR-FIOCRUZ/ MG), Belo Horizonte, Minas Gerais, Brazil; <sup>8</sup>Laboratório de Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou,

Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil; <sup>9</sup>Instituto de Biologia, Universidade Estadual de Campinas, SP, Brazil.

## Acknowledgements

This study was funded by Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM) (Pró-Estado Program - #002/2008 and PAPAC Program - #005/2019), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). WM, ML, FTMC, AM and PAN are research fellows from CNPq. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


PAN, WM and MVGL are CNPq research fellows.




**Figure 1. Comparison between Platelet counts in Pv-MAL patients and ENCG.**

A) Comparison of platelet counts in ENCG and Pv-MAL patients. Thrombocytopenia was defined as a platelet count less than 150,000/mm<sup>3</sup> and then classified as mild (50-150,000/mm<sup>3</sup>) and severe (<50,000/mm<sup>3</sup>) thrombocytopenia. Patients were classified as non-thrombocytopenic when they


had platelet counts above  $150,000/\text{mm}^3$ [36]. The individuals were grouped according in non-thrombocytopenic (green circle), mild (yellow circle) and severe thrombocytopenia (red circle). B) Comparison of MPV in Pv-MAL patients and ENCG; C) Comparison of PDW in Pv-MAL patients and ENCG.



**Figure 2. Comparison of parasitemia with Platelet indices.** A) Comparison of platelet indices according to parasitemia classified in  $\leq 500$  parasites/mm<sup>3</sup> and 501-to-20,000 parasites/mm<sup>3</sup>. B) Comparison of mean platelet volume (MPV) in relation to parasitemia; C) Comparison of platelet size heterogeneity (PDW) in relation to parasitemia. The individuals were grouped according in non-thrombocytopenic (green circle), mild (yellow circle) and severe thrombocytopenia (red circle).



**Figure 3. Comparison of correlations among platelet indices between Pv-MAL patients and ENCG.** A-C) Correlations between MPV and Platelet counts, PDW and Platelet counts, PDW and MPV in ENCG. D-F) Correlations between MPV and Platelet counts, PDW and Platelet counts, PDW and MPV in Pv-MAL. The individuals were grouped according in non-thrombocytopenic (green circle), mild (yellow circle) and severe thrombocytopenia (red circle).



**Figure 4. Comparison of serum concentrations of Th1/Th2/Th17 cytokines in ENCG and Pv-MAL.** The Th1/Th2/Th17 cytokines was dotted between ENCG and Pv-MAL patients. They were separated in a production order and serum concentrations, picogram per milliliter (pg/mL): A) IL-1 $\beta$ ; B) IL-6; C) IL-8; D) TNF; E) IL-2; F) IL-10; G) IL-12p70; H) IFN- $\gamma$ ; I) IL-4; J) IL-5 and K) IL-17A. The individuals were grouped according in non-thrombocytopenic (green circle), mild (yellow circle) and severe thrombocytopenia (red circle).

**Table. Multivariate analyses of Th1/Th2/Th17 cytokines associated with parasitemia (binomial) and platelet indices**

Mild parasitemia [Reference]	Logistic regression of Pv-MAL patients in relation to parasitemia			Linear regression predicting PDW between Pv-MAL patients and endemic controls		
	crude OR (CI 95%)	adjusted OR (CI 95%)	<i>p</i> (LR-test)	Patients [Reference]	Estimates (CI 95%)	<i>p</i> value
<b>Platelets</b>	1.00 (0.99, 1.00)	1.00 (0.99, 1.01)	0.510	<b>Platelets</b>	-0.01 (-0.01, 0.01)	0.315
<b>MPV</b>	1.01 (0.84, 1.21)	1.01 (0.75, 1.37)	0.947	<b>MPV</b>	-0.03 (-0.27, 0.20)	0.770
<b>PDW</b>	0.97 (0.82, 1.16)	0.99 (0.81, 1.21)	0.93	<b>PDW</b>	<b>1.44 (0.24, 2.63)</b>	<b>0.019</b>
<b>IL-1β</b>	1.02 (0.99, 1.06)	1.03 (0.99, 1.07)	0.100	<b>IL-1β</b>	<b>-0.03 (-0.05, -0.01)</b>	<b>0.047</b>
<b>IL-6</b>	1.00 (0.99, 1.00)	1.00 (0.99, 1.0001)	0.123	<b>IL-6</b>	-0.01 (-0.01, 0.01)	0.446
<b>IL-8</b>	1.00 (0.99, 1.01)	0.99 (0.98, 1.00)	0.197	<b>IL-8</b>	-0.01 (-0.01, 0.01)	0.801
<b>TNF</b>	1.00 (0.99, 1.01)	1.01 (0.99, 1.03)	0.312	<b>TNF</b>	0.01 (-0.01, 0.01)	0.371
<b>IL-2</b>	1.00 (0.98, 1.01)	0.99 (0.96, 1.01)	0.301	<b>IL-2</b>	<b>-0.02 (-0.04, -0.01)</b>	<b>0.030</b>
<b>IL-10</b>	<b>1.00 (1.00, 1.00)</b>	<b>1.00 (1.00, 1.00)</b>	<b>0.029</b>	<b>IL-10</b>	-0.01 (-0.01, 0.01)	0.573
<b>IL-12p70</b>	1.00 (0.99, 1.00)	1 (0.99, 1.00)	0.692	<b>IL-12p70</b>	<b>-0.01 (-0.01, -0.01)</b>	<b>0.038</b>
<b>IFN-γ</b>	1.00 (0.99, 1.00)	0.99 (0.99, 1.01)	0.900	<b>IFN-γ</b>	-0.01 (-0.01, 0.01)	0.413
<b>IL-4</b>	0.99 (0.99, 1.00)	0.99 (0.98, 1.00)	0.122	<b>IL-4</b>	0.01 (-0.01, 0.01)	0.833
<b>IL-5</b>	1.00 (0.96, 1.04)	0.99 (0.94, 1.04)	0.773	<b>IL-5</b>	0.04 (-0.01, 0.08)	0.052
<b>IL-17A</b>	<b>1.02 (1.00, 1.05)</b>	<b>1.03 (1.00, 1.07)</b>	<b>0.043</b>	<b>IL-17A</b>	-0.01 (-0.03, 0.02)	0.712

OR = odds ratio, CI 95% Confidence interval of 95%. MPV: mean platelet volume; PDW: platelet distribution width

## References

1. Patel U, Gandhi G, Friedman S, Niranjana S. Thrombocytopenia in malaria. *J Natl Med Assoc.* 2004;96:1212–4.
2. Wickramasinghe SNN, Abdalla SHH. Blood and bone marrow changes in malaria. *Baillieres Best Pract Res Clin Haematol.* 2000;13:277–99.
3. Saravu K, Docherla M, Vasudev A, Shastry BA. Thrombocytopenia in vivax and falciparum malaria: an observational study of 131 patients in Karnataka, India. *Ann Trop Med Parasitol* [Internet]. 2011;105:593–8. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4089803&tool=pmcentrez&endertype=abstract>
4. Lacerda MVGV, Mourão MP, Coelho HCCC, Santos JBB. Thrombocytopenia in malaria: who cares? *Mem Inst Oswaldo Cruz.* 2011;106 Suppl:52–63.
5. Lacerda MVG, Mourão MP, Alexandre M a, Siqueira AM, Magalhães BML, Martinez-Espinosa FE, et al. Understanding the clinical spectrum of complicated *Plasmodium vivax* malaria: a systematic review on the contributions of the Brazilian literature. *Malar J.* 2012;11:12.
6. Kochar DK, Tanwar GS, Khatri PC, Kochar SK, Sengar GS, Gupta A, et al. Clinical Features of Children Hospitalized with Malaria — A Study from Bikaner , Northwest India. *Am J Trop Med Hyg.* 2010;83:981–9.
7. Hanson J, Phu NH, Hasan MU, Charunwatthana P, Plewes K, Maude RJ, et al. The clinical implications of thrombocytopenia in adults with severe falciparum malaria: a retrospective analysis. *BMC Med* [Internet]. 2015;13:97. Available from: <http://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-015-0324-5>
8. Naing C, Whittaker MA. Severe thrombocytopenia in patients with vivax malaria compared to falciparum malaria: A systematic review and meta-analysis. *Infect Dis Poverty. Infectious Diseases of Poverty;* 2018;7:1–10.
9. Rahimi B, Thakkestian A, White NJ, Sirivichayakul C, Dondorp AM, Chokejindachai W. Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. *Malar J* [Internet]. 2014;13:481. Available from: <http://malariajournal.biomedcentral.com/articles/10.1186/1475-2875-13-481>
10. Tanwar GS, Khatri PC, Chahar CK, Sengar GS, Kochar A, Tanwar G, et al. Thrombocytopenia in childhood malaria with special reference to *P. vivax* monoinfection: A study from Bikaner (Northwestern India). *Platelets* [Internet]. 2012;23:211–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21864016>
11. Ramirez JF, Porras B, Borrero E, Martinez SP. Factors associated with the severity and complication of patients with malaria hospitalized between 2009 and 2013 in three municipalities of Colombia, case control study. *Malar J. BioMed Central;* 2016;15:514.
12. Cox D, McConkey S. The role of platelets in the pathogenesis of cerebral malaria. *Cell Mol Life Sci* [Internet]. 2010;67:557–568. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4055450&tool=pmcentrez&endertype=abstract>
13. Karanikas G, Zedwitz-Liebenstein K, Eidherr H, Schuetz M, Sauerman R, Dudczak R, et al. Platelet kinetics and scintigraphic imaging in thrombocytopenic malaria patients. *Thromb Haemost.* 2004;91:553–7.
14. Grau GE, Mackenzie CD, Carr RA, Redard M, Pizzolato G, Allasia C, et al. Platelet

- Accumulation in Brain Microvessels in Fatal Pediatric Cerebral Malaria. *J Infect Dis* [Internet]. 2003;187:461–6. Available from: <https://academic.oup.com/jid/article-lookup/doi/10.1086/367960>
15. White VA, Lewallen S, Beare NA V, Molyneux ME, Taylor TE. Retinal pathology of pediatric cerebral malaria in Malawi. *PLoS One*. 2009;4:1–8.
  16. MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA. Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. *Am J Pathol* [Internet]. 1985;119:385–401. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/3893148><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1888001>
  17. Turner GD, Morrison H, Jones M, Davis TM, Looareesuwan S, Buley ID, et al. An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. *Am J Pathol* [Internet]. 1994;145:1057–69. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7526692><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1887431>
  18. De Mast Q, De Groot PG, Van Heerde WL, Roestenberg M, Van Velzen JF, Verbruggen B, et al. Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy. *Br J Haematol*. 2010;151:495–503.
  19. De Mast Q, Groot E, Lenting PJ, de Groot PG, McCall M, Sauerwein RW, et al. Thrombocytopenia and release of activated von Willebrand Factor during early *Plasmodium falciparum* malaria. *J Infect Dis*. 2007;196:622–8.
  20. Casals-pascual C, Kai O, Newton CRJC, Peshu N, Roberts DJ. Short Report : Thrombocytopenia in *Falciparum* Malaria Is Associated With High Concentrations of IL-10. *Am J Trop Med Hyg*. 2006;75:434–6.
  21. Coelho HC, Lopes SC, Pimentel JP, Nogueira PA, Costa FTM, Siqueira AMM, et al. Thrombocytopenia in *Plasmodium vivax* malaria is related to platelets phagocytosis. *PLoS One*. 2013;e63410.
  22. Geddis AE. Megakaryopoiesis. *Semin Hematol*. 2010;47:212–9.
  23. Leowattana W, Tangpukdee N, Thar SK, Nakasiri S, Srivilairit S, Kano S, et al. Changes in platelet count in uncomplicated and severe *falciparum* malaria. *Southeast Asian J Trop Med Public Heal*. 2010;41:1035–41.
  24. Müller-Newen G, Stope MB, Kraus T, Ziegler P. Development of platelets during steady state and inflammation. *J Leukoc Biol*. 2017;101:1109–17.
  25. Behrens K, Alexander WS. Cytokine control of megakaryopoiesis. *Growth Factors* [Internet]. Taylor & Francis; 2018;36:89–103. Available from: <https://doi.org/10.1080/08977194.2018.1498487>
  26. De Mast Q, Groot E, Asih PB, Syafruddin D, Oosting M, Sebastian S, et al. ADAMTS13 deficiency with elevated levels of ultra-large and active von willebrand factor in *P. falciparum* and *P. vivax* malaria. *Am J Trop Med Hyg*. 2009;80:492–8.
  27. De Mast Q, Van Dongen-Lases EC, Swinkels DW, Nieman AE, Roestenberg M, Druilhe P, et al. Mild increases in serum hepcidin and interleukin-6 concentrations impair iron incorporation in haemoglobin during an experimental human malaria infection. *Br J Haematol*. 2009;145:657–64.
  28. Leal-Santos FA, Silva SBR, Crepaldi NP, Nery AF, Martin TOG, Alves-Junior ER, et al. Altered platelet indices as potential markers of severe and complicated malaria caused by *Plasmodium vivax*: a cross-sectional descriptive study. *Malar J* [Internet]. 2013;12:462. Available from:

<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3893420&tool=pmcentrez&endertype=abstract>

29. Langhorne J, Ndungu FMM, Sponaas A-M, Marsh K. Immunity to malaria: more questions than answers. *Nat Immunol* [Internet]. 2008;9:725–32. Available from: <http://www.nature.com/ni/journal/v9/n7/full/ni.f.205.html>
30. Raza A, Ghanchi NK, Zubairi ABS, Raheem A, Nizami S, Beg MA. Tumor necrosis factor alpha, interleukin-10, intercellular and vascular adhesion molecules are possible biomarkers of disease severity in complicated *Plasmodium vivax* isolates from Pakistan. *PLoS One*. 2013;8:1–9.
31. Pain A, Ferguson DJ, Kai O, Urban B, Lowe B, Marsh K, et al. Platelet-mediated clumping of *Plasmodium falciparum*-infected erythrocytes is a common adhesive phenotype and is associated with severe malaria. *Proc Natl Acad Sci U S A*. 2001;98:1805–10.
32. Park J, Park S, Yeom J, Huh A, Cho Y, Ahn J, et al. Serum cytokine profiles in patients with *Plasmodium vivax* malaria: a comparison between those who presented with and without thrombocytopenia. *Ann Trop Med Parasitol* [Internet]. 2003;97:339–44. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12556157>
33. Maina RN, Walsh D, Gaddy C, Hongo G, Waitumbi J, Otieno L, et al. Impact of *Plasmodium falciparum* infection on haematological parameters in children living in Western Kenya. *Malar J* [Internet]. 2010;9 Suppl 3:S4. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3002140&tool=pmcentrez&endertype=abstract%5Cnhttp://www.malariajournal.com/content/9/S3/S4>
34. *Bulletim of malaria situation in Amazonia, Brazil*. 2014 [Internet]. 2014 [cited 2014 Jun 24]. Available from: [http://portalweb04.saude.gov.br/sivep\\_malaria/default.asp](http://portalweb04.saude.gov.br/sivep_malaria/default.asp)
35. Ministério da saúde - SVS. SIVEP - Brazilian system for Malaria Notification [Internet]. Brazilian Healthy Ministry; 2015. Available from: [www.saude.gov.br/sivep\\_malaria](http://www.saude.gov.br/sivep_malaria)
36. Lampah DA, Yeo TW, Malloy M, Kenangalem E, Douglas NM, Ronaldo D, et al. Severe malarial thrombocytopenia: A risk factor for mortality in Papua, Indonesia. *J Infect Dis*. 2015;211:623–34.
37. Plebani M, Gillery P, Lackner K, Lippi G, Melichar B, Payne D, et al. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2010.
38. Jackson SR, Carter JM. Platelet volume: Laboratory measurement and clinical application. *Blood Rev*. 1993;7:104–13.
39. Gupta P, Guddattu V, Saravu K. Characterization of platelet count and platelet indices and their potential role to predict severity in malaria. *Pathog Glob Health* [Internet]. Taylor & Francis; 2019;113:86–93. Available from: <https://doi.org/10.1080/20477724.2019.1600855>
40. Punnath K, Dayanand KK, Chandrashekar VN, Achur RN, Kakkilaya SB, Ghosh SK, et al. Clinical features and haematological parameters among malaria patients in Mangaluru city area in the southwestern coastal region of India. *Parasitol Res. Parasitology Research*; 2020;119:1043–56.
41. Gupta P, Guddattu V, Saravu K. Characterization of platelet count and platelet indices and their potential role to predict severity in malaria. *Pathog Glob Health* [Internet]. Taylor & Francis; 2019;113:86–93. Available from: <https://doi.org/10.1080/20477724.2019.1600855>
42. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. *Int J Clin Pract*. 2009;63:1509–15.
43. Andrade BB, Reis-Filho A, Souza-Neto SM, Clarêncio J, Camargo LM a, Barral A,

- et al. Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. *Malar J*. 2010;9:13.
44. Punnath K, Dayanand KK, Chandrashekar VN, Achur RN, Kakkilaya SB, Ghosh SK, et al. Association between Inflammatory Cytokine Levels and Thrombocytopenia during Plasmodium falciparum and P. vivax Infections in South-Western Coastal Region of India . *Malar Res Treat*. 2019;2019:1–10.
45. Raza A, Khan MS, Ghanchi NK, Raheem A, Beg MA. Tumour necrosis factor, interleukin-6 and interleukin-10 are possibly involved in Plasmodium vivax-associated thrombocytopenia in southern Pakistani population. *Malar J* [Internet]. 2014;13:323. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4141950&tool=pmcentrez&endertype=abstract>
46. Yildiz Zeyrek F, Kurcer M a., Zeyrek D, Simsek Z. Parasite density and serum cytokine levels in Plasmodium vivax malaria in Turkey. *Parasite Immunol*. 2006;28:201–7.
47. Da-Costa A, Antonelli L, Costa P, Pimentel J, Garcia N, Tarragô A, et al. The robust and modulated biomarker network elicited by the Plasmodium vivax infection is mainly mediated by the IL-6/IL-10 axis and is associated with the parasite load. *J Immunol Res*. 2014;2014:318250.
48. Chaves YO, da Costa AG, Pereira MLM, de Lacerda MVG, Coelho-dos-Reis JG, Martins-Filho OA, et al. Immune response pattern in recurrent Plasmodium vivax malaria. *Malar J* [Internet]. *BioMed Central*; 2016;15:445. Available from: <http://malariajournal.biomedcentral.com/articles/10.1186/s12936-016-1501-5>
49. Freitas do Rosario AP, Langhorne J. T cell-derived IL-10 and its impact on the regulation of host responses during malaria. *Int J Parasitol*. Australian Society for Parasitology Inc.; 2012;42:549–55.
50. Rubio E, Alejo-Cancho I, Aylagas C, Camprubí D, Ferré R, Albarracín MR, et al. Diagnostic value of platelet and leukocyte counts in the differential diagnosis of fever in the returning traveler. *Am J Trop Med Hyg*. 2019;100:470–5.